title: Editorial Comment: Does gut-derived inflammation enhance pain signaling following chemotherapy in a Toll-like receptor 4-dependent manner?
authors: aDiscipline of Anatomy and Pathology bDiscipline of Physiology, School of Medical Sciences, University of Adelaide, South Australia, Australia *Hannah R. Wardill and Ysabella Z.A. Van Sebille contributed equally to the writing of this article.
authors: Hannah R
authors: HR
authors: Wardill
authors: Ysabella Z A
authors: YZ
authors: Van Sebille
authors: Joanne M
authors: JM
authors: Bowen
authors: Rachel J
authors: RJ
authors: Gibson
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000276:immunology / Q000627:therapeutic use; D006801:Humans; D007249:Inflammation / Q000150:complications / Q000503:physiopathology*; D007422:Intestines / Q000276:immunology* / Q000503:physiopathology; D009369:Neoplasms / Q000150:complications / Q000188:drug therapy; D009457:Neuroglia / Q000276:immunology* / Q000502:physiology; D010146:Pain / Q000139:chemically induced* / Q000276:immunology / Q000503:physiopathology; D015398:Signal Transduction / Q000276:immunology; D051197:Toll-Like Receptor 4 / Q000276:immunology* / Q000502:physiology
chemical_list: D000970:Antineoplastic Agents; C495345:TLR4 protein, human; D051197:Toll-Like Receptor 4